Patchliner Safety Edition.

Straightforward cardiac safety.

Patchliner Safety Edition

Comprehensive safety testing
104302nAnA

5-51-10-120-8010mV-40nA

402-5-10-120-80mV

42-5-120-40

40-1

42-51nAnA

30-10-80nA

mV-40

40

32-540-151nA-120
10-10-80nA

mV-40

604-540-1

52nA-12010-10-120-80

10mV

40-40

2.0
1.5
1.0
0.50-5nA

2.55• Exceptional support from Nanion CiPA experts-10-120-80mV-4040--0.5

10nA0420.00.2

0.4

0.6

0.8

1.0

1.2-120-80

mV-40nA65-5-10Patchliner
Safety Edition

mV5nA• Dynamic clamp for action potential recordings of hiPSC-derived cardiomyocytes-8010• Temperature control for measurements at physiological temperature• Patchliner CoolingPlate for viability of cells and stability of compounds

1nAnA

30-10

• Ready to use safety pharmacology protocols and analysis routines• Installation and training focussed on safety pharmacology experiments

40-40105• Pre-loaded routines and SOPs for hERG, NaV1.5-peak, NaV1.5-late and CaV1.2nA

65Patchliner Safety Edition features:40-140

Nanion EuropeNanion USANanion China

Nanion Japan

info@nanion.de

info@naniontech.com

andy.di@nanion.cn

ohtsuki@nanion.jp

phone: +49 89 2 190 95-0

phone: 1-888-9-NANION

phone: +86 10 82 17 63 86

phone: +81 3 6457 8776

www.nanion.de			Fast and reliable cardiac safety screening“Late compound withdrawal due to cardiac safety lia-HESI Think Tank Meeting. The new paradigm aims atbility issues is costly and inefficient. Platforms are re-mechanistic understandings of ventricular arrhythmias

quired supporting reliable compound testing in earlyby assessing multiple human cardiac currents anddevelopment. The Patchliner has drastically improvedtion potentials in stem cell-derived cardiomyocytes inthe efficiency of our safety testing by applying a highcombination with in silico modeling of ventricular myo-

degree of automation to otherwise manually per-cyte physiology. The combination of cardiac network

formed low throughput patch clamp experiments withmeasurements followed by high quality patch clamp

maintained data quality. The compatibility with stem

increase the possibility substantially, to quickly and cor-cells is extraordinary, a vital feature regarding the up-

rectly assess a compound’s cardiotoxicity profile”

coming need for the Comprehensive in vitro Proarrhyth-Dr. Liudmila Polonchuk, Principal Scientist, Non-Clinicalmia Assay (CiPA) recently discussed at the FDA/CSRC/

Safety, F. Hoffmann La RochehERGDMSO control
10 nM Cisapride
30 nM Cisapride
100 nM Cisapride
300 nM Cisapride
Full block

35°C1.0CiPA recommendations addressed

Cisapride (n = 7)
IC50 = 109 ± 20 nM

0.8• NaV1.5-peak and NaV1.5-late

0.60.4• Stable and reproducible CaV1.20.20.0

1 nA
100 ms

1.00.8100 pM

1 nM

10 nM

100 nM

1 µM• CiPA recommended protocols for hERG including

10 µM[Cisapride]

Control (60 nM ATX-II)
30 µM Lidocaine
2 mM Lidocaine

0.6

dynamic hERG (Milnes protocol)

NaV1.5-late

NaV1.5-peak

NaV1.5-late (n = 17)
IC50 = 23.6 µMac-• Standard operating procedures for all CiPA

0.5 nA
50 ms

0.4

recommended ion channels provided

0.20.0100 nM

1 µM
10 µM[Lidocaine]

100 µM• Recordings at room and physiological temperature

50 pA
10 ms

CaV1.2
1.00.8Control
100 nM Verapamil
1 µM Verapamil
10 µM Verapamil
100 µM Verapamil• Up to 8 simultaneous recordings

Verapamil (n = 8)
IC50 = 4.7 ± 0.9 µM• Powerful and efficient data analysis

0.60.4• Up to 500 data points per day

0.20.5 nA
50 ms

0.01 nM• Cost-efficient consumables

10 nM 100 nM 1 µM 10 µM 100 µM[Verapamil]

Current and dynamic clamp

Pharmacology on action potentials• hiPSC-derived cardiomyocytes
Current clamp• Pharmacology on action potentials in current clamp

Control
10 µM Nifedipine

mode

0 mV

• The only automated patch clamp platform on themarket which includes dynamic clamp

20 mV
40 ms

Dynamic clamp• Several different hiPSC-CMs validated

control-180 pA constant current

1 µM BayK 8644

800 pS/pF
0 mV

900 pS/pF
1000 pS/pF

30 µM Nifedipine
0 mV

1500 pS/pF

temperature

2000 pS/pF
40 mV
50 ms

• Current clamp recordings at room and physiological

20 mV
50 ms

• Complementary impedance/EFP device alsoavailable

Patchliner Safety Edition. All you need for cardiac safety screening.